TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06590363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to zen music
Description: We conducted a quasi-randomized controlled clinical trial with two groups: Intervention Group (I), which corresponded to patients and doctors who underwent the period of musical listening in the office; and the Control Group (C), composed of patients and doctors who did not undergo the period of musical listening.
Study: NCT06600178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Oral Tablet
Description: Dapagliflozin 10mg oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet given to subject vs. active drug.
Study: NCT04788316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBI and Text messaging
Description: A computerized brief intervention (2 sessions) followed by six months of personalized text messaging
Study: NCT05074979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercise program
Description: While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: informed program
Description: will informed after COVID 19
Study: NCT06600191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capstan System transcatheter mitral valve replacement
Description: This is a first human use trial exploring a novel transcatheter mitral valve replacement implant and electro-mechanical delivery system. The device offers a minimally invasive repair for patients who have at symptomatic regurgitation who are otherwise ineligable for surgical intervention, or who have no other prospects for treatment and in whom medical therapy has already been optimised.
Study: NCT06588270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy for the Negative Symptoms of Schizophrenia
Description: VRTNSS is a 12-session therapy using psychological intervention principles. Each therapy session will involve engaging with different VR based tasks where participants can experience different activities.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham- VR
Description: Patients will attend to VR sessions without the software created activities for treatment (sham-VR).
Study: NCT06592209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Breaks
Description: Participants recruited through a podcast series (Body Electric) produced by National Public Radio were asked to select one of three movement break conditions (5 minutes of movement for every 30-, 60-, or 120-minutes of sedentary time). Participants are asked to complete movement breaks during all waking hours on weekdays and weekends (i.e. 7 days a week). During movement breaks, participants are instructed to walk for 5 minutes in whichever way was most comfortable and safe (i.e. self-selected pace and location). Participants who use an assistive device such as a wheelchair or walker, were instructed to wheel, walk, or complete other convenient, comfortable, and safe types of movement such as upper body exercises with resistance bands, chair-based exercises, etc. No break reminders were provided, although participants were encouraged to set reminders in their phones or to utilize commercially available apps or wearable devices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Breaks
Description: Participants recruited through a podcast series (Body Electric) produced by National Public Radio were asked to select one of three movement break conditions (5 minutes of movement for every 30-, 60-, or 120-minutes of sedentary time). Participants are asked to complete movement breaks during all waking hours on weekdays and weekends (i.e. 7 days a week). During movement breaks, participants are instructed to walk for 5 minutes in whichever way was most comfortable and safe (i.e. self-selected pace and location). Participants who use an assistive device such as a wheelchair or walker, were instructed to wheel, walk, or complete other convenient, comfortable, and safe types of movement such as upper body exercises with resistance bands, chair-based exercises, etc. No break reminders were provided, although participants were encouraged to set reminders in their phones or to utilize commercially available apps or wearable devices.
Study: NCT05109754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP EFL
Description: Non-invasive ventilation using a novel ventilatory mode targeting expiratory flow limitation in COPD
Study: NCT06257524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and training
Description: Pediatric resource toolkits availability via TREKK for Kids Ongoing interactions, and intensive training and education sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and training
Description: Pediatric resource toolkits availability via TREKK for Kids Ongoing interactions, and intensive training and education sessions
Study: NCT05898243

Intervention type: PROCEDURE
Intervention: Reduction
Description: An Rx will be performed before and after the reduction of the dislocation. After that, the neurovascular state will be checked and also if there is some associated injury.
Study: NCT06592209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Breaks
Description: Participants recruited through a podcast series (Body Electric) produced by National Public Radio were asked to select one of three movement break conditions (5 minutes of movement for every 30-, 60-, or 120-minutes of sedentary time). Participants are asked to complete movement breaks during all waking hours on weekdays and weekends (i.e. 7 days a week). During movement breaks, participants are instructed to walk for 5 minutes in whichever way was most comfortable and safe (i.e. self-selected pace and location). Participants who use an assistive device such as a wheelchair or walker, were instructed to wheel, walk, or complete other convenient, comfortable, and safe types of movement such as upper body exercises with resistance bands, chair-based exercises, etc. No break reminders were provided, although participants were encouraged to set reminders in their phones or to utilize commercially available apps or wearable devices.
Study: NCT05469386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride ER
Description: Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride ER
Description: Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride ER
Description: Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral classroom
Description: Enhanced positive behavior supports implemented in classroom

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral classroom
Description: Enhanced positive behavior supports implemented in classroom

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral classroom
Description: Enhanced positive behavior supports implemented in classroom

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Classroom
Description: General education classroom procedures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Classroom
Description: General education classroom procedures

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Classroom
Description: General education classroom procedures

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic Accommodations
Description: Accommodations are introduced to support the child's independent seat work completion and quiz scores

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Accommodations
Description: Accommodations are introduced to support the child's independent seat work completion and quiz scores

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Academic Accommodations
Description: Accommodations are introduced to support the child's independent seat work completion and quiz scores

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Accommodations
Description: Accommodations are introduced to support the child's independent seat work completion and quiz scores
Study: NCT04522388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Enlive
Description: Ensure Enlive shake twice a day
Study: NCT05130528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor Intervention
Description: Infants in the experimental group will receive 2 sensorimotor intervention sessions in the Neonatal Intensive Care Unit (NICU) and 8 sensorimotor intervention sessions in the home or in a clinic (parent choice) at 1, 3, 5, 8, 11, 15, 20, 26 weeks post NICU discharge. The 2 intervention sessions in the NICU will consist of collaborating with parents to recognize their infant's cues to engage in interaction, readiness for sensory exposures, and anticipatory guidance on the transition to home. The 8 intervention sessions in the home will focus on supporting the parents to read their infant's cues to identify the ideal times for interaction and provide 20 minutes of daily intervention addressing four key principles: encourage 1) self-initiated movement, 2) movement variability, 3) visual and manual object interaction, and 4) social interaction. Parents are encouraged not to impose movement on the infant but to encourage movement through environmental enrichment
Study: NCT05074056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: We will administer intraoperative ketorlac.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: We will administer intraoperative ketorlac.
Study: NCT06016114

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV Latency Diagnostic Sampling
Description: This intervention involves the collection of blood, lymph node, colon biopsy, and placental samples from individuals living with HIV (HIV controllers) and healthy controls. The goal is to investigate HIV latency by analyzing these biological samples to gain insights into the mechanisms and characteristics of latent HIV reservoirs. The sampling procedures will be conducted using minimally invasive techniques where appropriate, and the collected samples will undergo laboratory analysis for further study.

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV Latency Diagnostic Sampling
Description: This intervention involves the collection of blood, lymph node, colon biopsy, and placental samples from individuals living with HIV (HIV controllers) and healthy controls. The goal is to investigate HIV latency by analyzing these biological samples to gain insights into the mechanisms and characteristics of latent HIV reservoirs. The sampling procedures will be conducted using minimally invasive techniques where appropriate, and the collected samples will undergo laboratory analysis for further study.
Study: NCT05162976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Given PO
Study: NCT06413121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV
Description: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV
Description: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
Study: NCT06035068

Intervention type: DRUG
Intervention: Indocyanine green
Description: Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.
Study: NCT05683457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT05527977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensation Incentives to improve Clinical Documentation
Description: The investigators have identified six Diagnoses of Interest for the initiative. For each Diagnosis of Interest, the investigators have specified a series of clinically significant diagnostic details. Each physician will receive a compensation bonus from a pool of $20,000 based on the absolute number of times that he or she appropriately documented a Diagnosis of Interest.~The investigators will use SQL Server Management Studio 18.0 to create an initial dataset using ICD-10 codes from office visits during which a Diagnosis of Interest was addressed. The investigators will compare documentation during the 12-week against a 6-week period prior to the intervention. The 6-week period will not be used to determine compensation bonuses. Two blinded research assistants will review H\&P's and progress notes from extracted visits to tabulate the number of times that clinical documentation met expectations.
Study: NCT05949736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Online intervention platform
Description: Music Therapy (MT) is known to have a calming effect on individuals by using relaxing and soothing music, gradually inducing a state of relaxation. Moreover, it can effectively regulate individual psychological emotions through its influence on specific brain regions such as the cerebral cortex, hypothalamus, and limbic system. This regulation of emotional responses can lead to an improvement in daily mood, reducing feelings of tension and anxiety.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Online intervention platform
Description: Music Therapy (MT) is known to have a calming effect on individuals by using relaxing and soothing music, gradually inducing a state of relaxation. Moreover, it can effectively regulate individual psychological emotions through its influence on specific brain regions such as the cerebral cortex, hypothalamus, and limbic system. This regulation of emotional responses can lead to an improvement in daily mood, reducing feelings of tension and anxiety.
Study: NCT06233240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Metformin Hydrochloride Tablets Test product
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Mankind Pharma Limited, India

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Metformin Hydrochloride Tablets Reference product
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
Study: NCT06311487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted-AM
Description: Participants will engage in aerobic exercise within 4 hours of waking up, following a \>10h overnight fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~08:00, \~13:00, and \~19:00. Plasma metabolite samples will be drawn immediately pre- and post- exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fed-AM
Description: Participants will engage in exercise within 4 hours of waking up, approximately 1h after consuming breakfast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted-PM
Description: Participants will engage in exercise between 8-12 hours after waking up, following a \~10h fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00 and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fed-PM
Description: Participants will engage in exercise between 8-12 hours after waking up, approximately 1h after consuming dinner across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
Study: NCT04968002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pablizumab combined with apatinib and neoadjuvant chemotherapy
Description: The patients with stage IIa-IIIa non-small cell lung cancer are treated with pablizumab combined with apatinib and neoadjuvant chemotherapy
Study: NCT05951933

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Strenghtening + TES
Description: Strenghtening of rotator cuff and scapulothoracic muscles protocol with the incorporation of anodal transcranial direct stimulation (real if experimental or sham if control)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strenghtening + TES
Description: Strenghtening of rotator cuff and scapulothoracic muscles protocol with the incorporation of anodal transcranial direct stimulation (real if experimental or sham if control)
Study: NCT04927195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1867
Description: EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1867
Description: EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1867
Description: EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1867
Description: EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1867
Description: EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT05417646

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyperglycaemic clamp
Description: Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycaemic clamp
Description: Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyperglycaemic clamp
Description: Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycaemic clamp
Description: Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to empagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Single-dose, 25 mg, two hours before clamp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Single-dose, 25 mg, two hours before clamp
Study: NCT05600634

Intervention type: PROCEDURE
Intervention: Skin allotransplantation
Description: Sentinel skin grafts from the same donor source will be carried on in the meantime of kidney transplantation for assisting to detect acute renal rejection.
Study: NCT05348538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review with follow up or MaJ? for the acronym in french
Description: MaJ? service will involve a pharmacist-patient face-to-face consultation with a 6-months interval during the study, it includes:~1. Educational training: pharmacists will attend a half a day course. They will inform pharmacy technicians of their tasks. They will also have available an online version of the training about the service and data collection.~2. Service provision: before the pharmacist-patient consultation (pharmacy technicians review the medication to identify the prescribed medication included in the treatment plan and to remove expired or medications non taken by the patient), during (pharmacist assess potential drug related problem) and after the consultation (to send a medication management plan to patients and doctors).~3. Practice change facilitation to support pharmacists: pharmacists will be follow-up by the research team during the study (1st, 2nd, 3rd, 6th, 12th and 15th months of the study) to support them through the delivery of the service.